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Abstract: Numerous studies determined that the neutrophil/lymphocyte (NLR) and 
platelet/lymphocyte ratios (PLR) had prognostic value in several cancer types. This 
study aimed to evaluate the relationship between NLR and PLR values with the 
survival time of lung cancer patients. Patients diagnosed with lung cancer between 
January 2014 and December 2016, were retrospectively evaluated. Demographic 
characteristics, disease stages, laboratory parameters recorded, and the relationship 
of NLR and PLR values with the survival time and the disease stage evaluated. NLR 
and PLR were categorized into two groups. SPSS 17.0 software package was used 
for the statistical analysis. ROC analysis, Student T-test, Chi-square, and Mann-
Whitney U test were used. Mean age of 62±8 years were included in the study. In 
the NSCLC group, the average NLR and PLR values were 4±3.35 and 194.6±144.4 
respectively. Regarding the NSCLC group, the overall survival time was shorter in 
the subgroup with an NLR >3.43 (13.1 months) compared to the subgroup with an 
NLR ≤3.43 (24.3 months). The mean survival time was shorter in the group with a 
PLR > 136.9 compared to the group with a PLR ≤136.9 (15.9 and 24.6 months 
respectively). Subgroups consisting of survivors and non-survivors in the NSCLC 
group showed a statistically significant difference considering neutrophil and 
lymphocyte count, CRP, NLR, and PLR values (p<0.05). As NLR and PLR values 
are easily accessible, they have an essential role in the prognosis of lung cancer as 
well as other cancer types. 
Keywords: lung cancer; neutrophil to lymphocyte ratio; platelet to lymphocyte ratio; 
prognosis; survival time 
 
INTRODUCTION 
Lung cancer is the leading cause of cancer deaths worldwide. Approximately 
85% of lung cancer cases constitute of non-small cell lung cancer (NSCLC) and 15% 
of small cell lung cancer (SCLC). Despite the advances in diagnosis and treatment, 
lung cancer has still a poor prognosis (Siegel et al., 2013). Was demonstrated that 
one of the most important determinants of survival was the stage of the tumor. Other 
factors that affect prognosis are gender, age, and weight loss. In addition, it was 
found out that specific laboratory parameters measured before the treatment have 
also an important role in the prognosis (e.g. lactate dehydrogenase (LDH), alkaline 
phosphatase (ALP), albumin, carcinoembryonic antigen) (Bremnes et al., 2003; 
Douillard et al., 2010; Tanner et al., 2012) Inflammation also considered as a critical 
factor with its effects on the tumor development and progression. However, it is also 
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well known that angiogenesis, metastasis, and the response to the treatment are 
also important factors.  
Neutrophils, T lymphocytes, and B lymphocytes are considered as factors that 
play a vital role in tumor inflammation. The imbalance between neutrophils and 
lymphocytes is secondary to the tumor hypoxia or necrosis, which may be related to 
the anti-apoptotic effects of the neutrophils (Mantovani, 2009; Schreiber et al., 2011). 
NLR may reflect the imbalance between neutrophils and lymphocytes in patients with 
the tumor. It functions as a representative index of the systemic inflammation. In 
various solid tumors, markers such as platelets, neutrophils, lymphocytes, NLR, and 
PLR have evaluated as indicators of systemic inflammatory response. Findings 
indicated that neutrophilia, lymphopenia and thrombocytosis were related to 
malignancies (S. Lee et al., 2013; Y. Lee et al., 2012). Platelets also have an 
important role in cancer progression. Platelets contribute to tumor growth by 
stimulating angiogenesis via vascular endothelial growth factor (VEGF). It was 
demonstrated that high NLR and PLR values are related to short survival time in the 
group with advanced stage NSCLC (Wu et al., 2015). NLR and PLR were an easily 
accessible and simple test. NLR and PLR may help to detect prognosis when 
carefully interpreted. In our study, we investigated the correlation between the NLR 
and PLR and prognosis in lung cancer patients treated with a standard regimen. 
 
MATERIALS AND METHODS 
In this retrospective study, the files of 280 patients, who were diagnosed with 
lung cancer in our clinic between January 2014 and December 2016, were 
evaluated. Demographic characteristics such as age, gender, pathological diagnosis, 
lung cancer cell type, disease stages, date of diagnosis, date of death of deceased 
patients, complete blood count (neutrophil, lymphocyte, thrombocyte, CRP, 
eosinophil) NLR, PLR and survival time recorded. NLR was calculated by dividing 
the absolute neutrophil count by the absolute lymphocyte count from a complete 
blood count and PLR was calculated by dividing the absolute platelet count by the 
absolute lymphocyte count. NLR and PLR values were categorized into 2 groups 
(NLR>3.43, NLR≤3.43; PLR>136.9, PLR≤136.9). 60 patients, who had a bacterial 
infection at that time, were not treated at all, were not treated according to the stage 
of the disease and had no laboratory results in their files, were excluded from the 
study. The relationship between NLR and PLR values of patients with survival time 
and disease stages investigated. The study protocol was approved by Kartal Dr. Lutfi 
Kirdar Training and Research Hospital institutional review board  
Data were analyzed with the SPSS 17.0 software package. For the descriptive 
data, mean values and percentage used. Student's T-test and Mann-Whitney U test 
were used for continuous variables. In the NSCLC group, regarding NLR and PLR 
values, cut-off values over a 1-year time interval were found, and the area under the 
ROC curve calculated for each of them. For this purpose, "survival ROC" package in 
R program was used. Youden J index was used for the determination of the cut-off 
values. NLR and PLR variables divided into two groups according to the calculated 
cut-off point and the survival probabilities compared between the groups with values 
over and under the cut-off point with the Log-rank test. P<0.05 was considered 
statistically significant.  
 
RESULTS AND DISCUSSION 
A total of 220 (181 NSCLC and 39 SCLC) patients with a mean age of 62±8 
years included in the study. 82.3% of the patients were males.  
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The demographic characteristics of the patients summarized in Table 1.  
In the NSCLC group, the mean NLR and PLR values were 4±3.5 and 
195.5±153.7, respectively. In the NSCLC group, the overall survival time was shorter 
in the subgroup with NLR>3.43 at diagnosis (13.1 months) compared to the 
subgroup with an NLR ≤3.43 (24.3 months). The mean survival time was shorter in 
the group with a PLR >136.9 compared to the group with a PLR≤136.9 (15.9 and 
24.6 months; p<0.0001and p=0.002 respectively) (Figure 2). There was no 
statistically significant difference between the NLR and PLR groups categorized 
according to the cut-off value in respect of age and gender (p> 0.05).  
Overall mean NLR and PLR values were 4.08±3.35 and PLR 194.6±144.4, 
respectively. There were statistically significant differences between survivors and 
non-survivors considering the neutrophil count, lymphocyte count, CRP, NLR and 
PLR values (p=0.02, p<0.001, p=0.002, p<0.001, p<0.001 respectively).  
 In the NSCLC group, there was statistically significant difference between 
survivors and non-survivors in respect of neutrophil count, lymphocyte count, CRP, 
NLR and PLR values  (p=0 .008, p = 0.003, p =0.002, p<0.0001; p=0.001 
respectively).  
The mean NLR and PLR values were 4.2±2.5 and 190.4±91.3, respectively, in 
the SCLC group. In the SCLC group, there was a statistically significant difference 
between survivors and non-survivors regarding lymphocyte count and PLR value 
(p=0.003; p=0.003, respectively). 
There was a statistically significant difference between the subgroups of 
SCLC group consisting of early and advanced stage patients regarding the CRP, 
NLR and PLR values (p<0.0001, p=0.001, p=0.028 respectively) (Table 2). The 
subgroups of the SCLC group consisting of the limited and advanced stages showed 
a statistically significant difference considering the lymphocyte count and PLR value 
(p=0.004, p=0.028, respectively) (Table 3).  
 
Table 1. Demographic and clinical characteristics of lung cancer patients 
 N Percentage 
CANCER TYPE   
 Adenocarcinoma 50 22.7% 
 Squamous cell 91 41.4% 
 NOS 40 18,2% 
 Small cell (SCLC) 39 17.7% 
CANCER TYPE-2   
 Non-small cell lung cancer (NSCLC) 181 82.3% 
 Small cell (SCLC) 39 17.7% 
STAGE-NSCLC   
 Early stage (1,2,3A) 88 48.6% 
 Advanced stage (3B,4) 93 51,4% 
STAGE–SCLC   
 Limited disease 10 25.6% 
 Diffuse disease 29 74.4% 
Survivors   
 NSCLC 79 43.6% 
 SCLC 10 25.6% 
Non-survivors   
 NSCLC 102 56.4% 
 SCLC 29 74.4% 
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Table 2. Hematological parameters in early and advanced stage  
non-small cell lung cancer 
NSCLC ADVANCED STAGE EARLY STAGE p-value 
N(10³/uL) 7.12±2.69 5.95±2.13 0.075 
L(10³/mm³) 1.89±0.69 2.06±0.79 0.084 
PLT(10³/uL) 329.4±103.2 306.7±94.2 0.178 
CRP (mg/L) 37.87±32.2 19.55±28.9 0.0001 
N/L 4.49±4.3 3.58±2.6 0.001 
PLT/L 208.1±191.3 182.9±115.7 0.028 
 
Table 3. Hematological parameters in limited and advanced stage 
small-cell lung cancer 
SCLC ADVANCED STAGE LIMITED STAGE P-value 
N(10³/uL) 6.76±2.1 7.73±2.3 0.757 
L(10³/mm³) 1.76±0.79 2.22±0.91 0.004 
PLT(10³/uL) 319.4±94.2 299.4±93.8 0.423 
CRP (mg/L) 33.80±28.8 15.52±11.3 0.223 
N/L 4.52±4.3 3.50±2.6 0.317 
PLT/L 206.9±115.7 136.6±178.7 0.028 
 
 
Figure 1: The mean survival time of the groups with NLR>3.43 and NLR≤3.43. 
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Figure 2: The mean survival time of the groups with PLR>136.9 and PLR≤ 36.9. 
 
In our study, when we take all patients with lung cancer into consideration, 
there was a statistically significant difference between the groups consisting of 
survivors and non-survivors in respect of neutrophil and lymphocyte count, CRP, 
NLR, and PLR values. There was a statistically significant difference between the 
survivors and non-survivors of the NSCLC group regarding the neutrophil and 
lymphocyte count, CRP, NLR, and PLR values. There was a statistically significant 
difference between the early and advanced stage patients of the NSCLC group 
considering CRP, NLR, and PLR values. 
The correlation between inflammation and cancer demonstrated in several 
studies. The contribution of the inflammation to the tumor development and 
angiogenesis is well known (Coussens and Werb, 2002). Studies had shown that 
inflammation increased the risk in several cancer types like colorectal and pancreatic 
carcinoma (Shim et al., 2005).  
Some systemic inflammatory markers are related to the clinical and 
pathological characteristics of the tumor. Neutrophils, T- and B-lymphocytes have a 
prominent role in tumor inflammation (Lin et al., 2012; Schreiber et al., 2011). It was 
determined in several studies, that the increased NLR value measured from the 
peripheral blood was an independent prognostic factor in esophagus, colon, stomach 
and lung cancers (Noh et al., 2013; Sharaiha et al., 2011). 
 In a study, 386 patients with lung cancer evaluated and it was determined 
that the median survival time was shorter in patients with NLR≥3 than in patients with 
NLR <3 (Akinci Ozyurek et al., 2017). In our study, we found out that the mean 
survival time was shorter in patients with NLR>3.43 than those with NLR ≤3.43. In a 
study conducted with stage 3B and four lung cancer patients, the pretreatment 
values of neutrophil count and NLR correlated with poor prognosis (Teramukai et al., 
2009). In our study, the comparison of survivors and non-survivors of the NSCLC 
group showed that there was a statistically significant difference between these 
groups in respect of neutrophil and lymphocyte count and NLR value. It suggested 
that these parameters were related to the poor prognosis in lung cancer patients. In 
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a study, a correlation was determined between the increased NLR value and poor 
prognosis (Cedres et al., 2012).  
In NSCLC patients with a resectable tumor, a correlation was demonstrated 
between the short survival time and NLR and CRP levels at the time of diagnosis 
(Tomita et al., 2011). In a study conducted by Ünal et al., 94 patients were 
investigated, and it was found out that there was a significant correlation between 
the increased pre-treatment NLR values and the survival rates (Unal et al., 2013). 
In another study, similar to our research, NLR was associated with short 
survival time in patients with advanced stage NSCLC (Yao et al., 2013). The meta-
analysis of 14 studies had shown that increased NLR value is correlated with the 
short survival time (Yin et al., 2015). Another study revealed that an NLR of < 3 at 2 
and four weeks after nivolumab treatment may be an independent prognostic 
biomarker in patients with advanced NSCLC (Nakaya et al., 2018).  
In our study, we were not able to evaluate the correlation between NLR and 
survival time in SCLC due to the limited number of subjects. Studies did not show 
any correlation between NLR and mean survival time in SCLC patients (Akinci 
Ozyurek et al., 2017). In another study focused on SCLC patients, it was shown that 
the high NLR value was an independent risk factor for survival (Deng et al., 2017). In 
a study conducted in 65 patients with limited-stage SCLC, it was found out that the 
NLR value was an independent risk factor for survival (Kasmann et al., 2017). In our 
study, there was no significant difference between survivors and non-survivors in the 
SCLC group regarding the mean NLR values. 
In the previous studies, it was determined that the platelet count was 
positively correlated with the lymph node metastasis and negatively correlated with 
the survival (H. B. Liu et al., 2013). PLR, which considered as an indicator of the 
systemic inflammation in recent years, was investigated in several centers for the 
determination of its relationship with the survival of lung cancer patients. In a study 
with NSCLC patients, similar to our study, the increased PLR value was correlated 
with the poor prognosis (H. Liu et al., 2013). In our study, we found out that the 
survival time was shorter in the group with PLR >136.9 than the group with 
PLR≤136.9. PLR is another indicator of the systemic inflammation, and some studies 
demonstrated that the activation of the platelets and the coagulation system is critical 
for the tumor metastasis. However, its mechanism has not fully elucidated (Bambace 
and Holmes, 2011; Gay and Felding-Habermann, 2011). In the subgroup of the 
metastatic NSCLC group consisting of the patients with high PLR value at diagnosis, 
the median survival time was shorter than the group with low PLR value at diagnosis 
(Diem et al., 2017). The study with operable NSCLC patients did not show a 
correlation between the PLR and survival time (Pinato et al., 2014). A meta-analysis 
of 3720 patients showed that high PLR values were associated with poor prognosis 
(Zhao et al., 2016). In our study, in the NSCLC group, PLR value was significantly 
higher among the survivors compared to the non-survivors. 
In a study with SCLC patients, the high PLR values were correlated to the 
poor prognosis (Deng et al., 2017). In our study, there was a significant difference 
between the survivors and non-survivors of the SCLC group. 
The retrospective study design, the different numbers of NSCLC and SCLC 
patients, the limited number of SCLC patients were the limitations of our study. 
When examined in conjunction with the literature, NLR and PLR have an 
important role in the inflammation of lung cancer as well as in other cancers. It is an 
easily accessible, simple, and inexpensive blood parameter, and it will shed some 
light on the prognosis when carefully interpreted. 
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CONCLUSION 
Subgroups consisting of survivors and non-survivors in the NSCLC group 
showed a statistically significant difference considering neutrophil and lymphocyte 
count, CRP, NLR, and PLR values (p<0.05). 
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